Pulmatrix, Inc. and Eos SENOLYTIX, Inc. have announced a definitive merger agreement, set to create a new entity named Eos SENOLYTIX, Inc., which will trade under the Nasdaq ticker “EOSX.” This strategic union aims to advance novel gerotherapeutic treatments focused on mitochondrial dysfunction and cellular senescence, with an initial focus on conditions like sarcopenia and age-related diseases. The merger is bolstered by $19 million in concurrent private financings.
The newly formed Eos SENOLYTIX will position itself as a leader in gerotherapeutics, a field dedicated to targeting the fundamental biological mechanisms of aging to enhance healthspan. The company’s lead clinical candidate, PTC-2105, developed using Eos’s proprietary MitoXcel™ platform, is designed to address sarcopenia and sarcopenic obesity. Preclinical studies have shown PTC-2105’s potential to improve body composition by reducing fat mass and increasing lean muscle mass, offering a differentiated approach compared to current weight-loss therapies like GLP-1 receptor agonists.
Eos’s AI-driven MitoXcel™ platform utilizes proprietary geropeptides to target mitochondrial dysfunction. This approach aims to rejuvenate mitochondrial function and selectively eliminate senescent cells. Beyond sarcopenia, the platform holds potential for treating a range of age-related diseases, including metabolic, cognitive, and neurodegenerative disorders. The company’s strategy emphasizes a shift in obesity treatment from solely focusing on weight reduction to optimizing body composition for improved health and longevity.
The merger provides Pulmatrix stockholders with an opportunity to participate in the growth of a company focused on addressing significant unmet medical needs. The $19 million in financing will support the advancement of Eos’s pipeline through key clinical milestones. Following the merger, pre-merger Eos stockholders, including investors in the concurrent financings, are expected to hold approximately 94% of the combined company, while pre-merger Pulmatrix stockholders are expected to own about 6%.
Kevin Slawin, M.D., Founder and CEO of Eos, will lead the combined entity. Dr. Slawin, who previously founded Bellicum Pharmaceuticals, brings extensive experience in drug development and company formation. The merger is anticipated to close in mid-2026, pending stockholder approvals and regulatory requirements. The combined company aims to leverage its scientific innovation and public market infrastructure to translate gerotherapeutic concepts into tangible clinical benefits.